Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

被引：77

作者：

Hu, Jiao ^{[1
,2
]}

Chen, Jinbo ^{[1
,2
]}

Ou, Zhenyu ^{[1
,2
,4
]}

Chen, Haige ^{[3
]}

Liu, Zheng

Chen, Minfeng ^{[1
,2
]}

Zhang, Ruiyun ^{[3
]}

Yu, Anze ^{[5
]}

Cao, Rui ^{[6
]}

Zhang, Enchong ^{[7
]}

Guo, Xi ^{[8
]}

Peng, Bo ^{[9
]}

Deng, Dingshan ^{[1
,2
]}

Cheng, Chunliang ^{[1
,2
]}

Liu, Jinhui ^{[1
,2
]}

Li, Huihuang ^{[1
,2
]}

Zou, Yihua ^{[10
]}

Deng, Ruoping ^{[11
]}

Qin, Gang ^{[11
]}

Li, Wenze

Wang, Lue ^{[12
,13
]}

Chen, Tao ^{[14
]}

Pei, Xiaming ^{[15
]}

Gong, Guanghui ^{[16
]}

Tang, Jiansheng ^{[17
]}

Othmane, Belaydi ^{[1
,2
]}

Cai, Zhiyong ^{[1
,2
]}

Zhang, Chunyu ^{[1
,2
]}

Liu, Zhi ^{[1
,2
]}

Zu, Xiongbing ^{[1
,2
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China

[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Wuhan, Peoples R China

[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China

[6] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China

[7] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China

[8] Hunan Normal Univ, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Dept Urol, Changsha, Peoples R China

[9] Zhangjiajie Peoples Hosp, Dept Urol, Zhangjiajie, Peoples R China

[10] First Peoples Hosp Chenzhou, Dept Urol, Chenzhou, Peoples R China

[11] Cent Hosp Yongzhou, Dept Urol, Yongzhou, Peoples R China

[12] First Peoples Hosp Xiangtan City, Dept Urol, Xiangtan, Peoples R China

[13] Huarong Peoples Hosp, Dept Urol, Yueyang, Peoples R China

[14] Xiangyang Cent Hosp, Dept Urol, Xiangyang, Peoples R China

[15] Hunan Canc Hosp, Dept Urol, Changsha, Peoples R China

[16] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China

[17] Xiangnan Univ, Affiliated Hosp, Dept Urol, Chenzhou, Peoples R China

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 11期

基金：

湖南省自然科学基金; 中国国家自然科学基金;

关键词：

PHASE-III TRIAL; UROTHELIAL CARCINOMA; TUMOR MICROENVIRONMENT; OPEN-LABEL; END-POINT; PEMBROLIZUMAB; CISPLATIN; OUTCOMES; TISLELIZUMAB; ATEZOLIZUMAB;

D O I：

10.1016/j.xcrm.2022.100785

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with mus-cle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi-center, real-world cohort study that enrolls 253 patients treated with neoadjuvant treatments (combination therapy: 98, chemo-therapy: 107, and immunotherapy: 48) from 15 tertiary hospitals. We demonstrate that neoadjuvant combi-nation therapy achieves the highest complete response rate and pathological downstaging rate compared with neoadjuvant immunotherapy or chemotherapy. We develop and validate an efficacy prediction model consisting of pretreatment clinical characteristics, which can pinpoint candidates to receive neoadjuvant combination therapy. We also preliminarily reveal that patients who achieve pathological complete response after neoadjuvant treatments plus maximal transurethral resection of the bladder tumor may be safe to receive bladder preservation therapy. Overall, this study highlights the benefit of neoadjuvant combination therapy based on tislelizumab for MIBC.

引用

页数：17

共 50 条

[31] Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A new standard of care? [J].

Harland, S .

BJU INTERNATIONAL, 2003, 92 (09) :877-878

[32] Impact of neoadjuvant chemotherapy on therapeutic management of muscle-invasive bladder cancer [J].

Meyer, V. ;

Flechon, A. ;

Tartas, S. ;

Fassi-Fehri, H. ;

Ruffion, A. ;

Martin, X. ;

Colombel, M. .

PROGRES EN UROLOGIE, 2015, 25 (02) :83-89

[33] Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer [J].

Miyagi, Hiroko ;

Kwenda, Elizabeth ;

Ramnaraign, Brian H. ;

Chatzkel, Jonathan A. ;

Brisbane, Wayne G. ;

O'Malley, Padraic ;

Crispen, Paul L. .

CANCERS, 2023, 15 (01)

[34] A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer [J].

Dracham, Chinna Babu ;

Kumar, Narendra ;

Kumar, Santosh ;

Elangovan, Arun ;

Yadav, Budhi Singh ;

Mavuduru, Ravimohan S. ;

Lal, Anupam ;

Gupta, Pramod K. ;

Kapoor, Rakesh .

ASIAN JOURNAL OF UROLOGY, 2022, 9 (03) :318-328

[35] Use of treatment pathway improves neoadjuvant chemotherapy use in muscle-invasive bladder cancer [J].

Faraj, Kassem S. ;

Navaratnam, Anojan K. ;

Eversman, Sarah ;

Elias, Laila ;

Syal, Amit ;

Tyson, Mark D. ;

Castle, Erik P. .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (06) :1111-1118

[36] Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer [J].

Alva, Ajjai S. ;

Tallman, Christopher T. ;

He, Chang ;

Hussain, Maha H. ;

Hafez, Khaled ;

Montie, James E. ;

Smith, David C. ;

Weizer, Alon Z. ;

Wood, David ;

Lee, Cheryl T. .

CANCER, 2012, 118 (01) :44-53

[37] Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer? [J].

Yafi, Faysal A. ;

Kassouf, Wassim .

EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) :747-752

[38] Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) [J].

Geynisman, Daniel M. ;

Abbosh, Philip H. ;

Ross, Eric ;

Zibelman, Matthew R. ;

Ghatalia, Pooja ;

Anari, Fern ;

Mark, James R. ;

Stamatakis, Lambros ;

Hoffman-Censits, Jean H. ;

Viterbo, Rosalia ;

Greenberg, Richard E. ;

Churilla, Thomas M. ;

Horwitz, Eric M. ;

Hallman, Mark A. ;

Smaldone, Marc C. ;

Uzzo, Robert ;

Chen, David Y. T. ;

Kutikov, Alexander ;

Plimack, Elizabeth R. .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09) :1113-1122

[39] Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer [J].

Meleis, Laura ;

Moore, Russell ;

Inman, Brant A. ;

Harrison, Michael R. .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) :330-337

[40] Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study [J].

von Rundstedt, Friedrich-Carl ;

Mata, Douglas A. ;

Kryvenko, Oleksandr N. ;

Shah, Anup A. ;

Jhun, Iny ;

Lerner, Seth P. .

BLADDER CANCER, 2017, 3 (01) :35-44

← 1 2 3 4 5 →